BioSig PURE EP System Featured in the Editorial of EP Lab Digest
Westport, CT, Jan. 14, 2021 (GLOBE NEWSWIRE) --
- Leading industry publication calls attention to ongoing challenges in the electrophysiology lab
- PURE EP System is highlighted as a novel technological solution
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced the PURE EP™ System was featured in the January issue of EP Lab Digest.
The editorial, authored by the Editor-in-Chief Bradley P. Knight, M.D., FACC, FHRS, highlights several challenges in electrophysiology (EP), including loss of essential components of the signal during the filtering process, inadequate signal-to-noise ratio, and saturation of the signals during pacing and defibrillation. According to Dr. Knight, the need for advancements in signal recording are long overdue. Novel techniques to improve EGM signal fidelity in EP labs are imperative for the efficacy of ablation procedures.
Dr. Knight highlights how the PURE EP™ System addresses these current limitations through its novel hardware architecture and its proprietary signal processing software. He further elaborates on the findings of the recent study titled “A novel cardiac signal processing system for electrophysiology procedures: early insights from the pure ep 2.0 study” recently presented during the European Society of Cardiology Congress 2020. The independent, blinded reviewers have rated 85% of the PURE EP™ signals as statistically equivalent or better based on the evaluations from 34 pairs of signals. In 35.5% of samples, the reviewers selected PURE EP™ data because "more signal components were visible." Read the full article here.
“We are committed to solving unmet clinical needs through innovative technological solutions, and we are very pleased with the growing industry recognition of our PURE EP™ System. We look forward to expanding our physician collaborations in 2021 and reporting on more clinical insights,” commented Kenneth L. Londoner, Chairman, and CEO of BioSig Technologies, Inc.
This is the latest editorial in a series of publications featuring BioSig’s PURE EP™ System in the industry-leading media outlets. PURE EP™ System was recently highlighted in several physician user’s interviews, including the December 2020 feature interview with Rafaelle Corbisiero, M.D. and Pedram Kazemian, M.D. of Deborah Heart and Lung Center and April 2020 interview with Andrea Natale, M.D. of Texas Cardiac Arrhythmia Institute at St. David’s Medical Center.
About BioSig Technologies
BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals (www.biosig.com).
The Company’s first product, PURE EPä System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording, and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory.
Forward-looking Statements
This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward- looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) the geographic, social and economic impact of COVID-19 on our ability to conduct our business and raise capital in the future when needed, (ii) our inability to manufacture our products and product candidates on a commercial scale on our own, or in collaboration with third parties; (iii) difficulties in obtaining financing on commercially reasonable terms; (iv) changes in the size and nature of our competition; (v) loss of one or more key executives or scientists; and (vi) difficulties in securing regulatory approval to market our products and product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
Andrew Ballou BioSig Technologies, Inc. Vice President, Investor Relations 54 Wilton Road, 2nd floor Westport, CT 06880 aballou@biosigtech.com 203-409-5444, x133
Released January 14, 2021
